The dexamethasone suppression test and antidepressant response in major depression.
We conducted a prospective open pilot study of 34 consecutively admitted patients with the DSM-III diagnosis of MD who were admitted to a general psychiatric unit. Patients underwent a 1 mg DST and were randomly assigned to treatment with either maprotiline or trazodone. Antidepressant dosages were increased as tolerated clinically and according to treatment response.


RESULTS
mean final oral doses were 193 mg for maprotiline and 328 mg for trazodone. The mean treatment duration was 4.5 weeks for maprotiline and 5.9 weeks for the trazodone group. Of these 34 patients 44% showed DST nonsuppression (41% maprotiline, 45% trazodone). Seventy-six per cent of the patients responded to treatment (76% for both drugs) as defined by GAS. Eighty-seven per cent of the nonsuppressors responded to treatment (86% maprotiline, 88% trazodone) and 68% of the suppressors responded (70% maprotiline, 67% trazodone). Of the eight treatment nonresponders six showed DST suppression. The implications of these findings are discussed.
Simon
J S
JS
University of Wisconsin Medical School, Milwaukee 53201.
Evans
D L
DL
Nemeroff
C B
CB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D003907:Dexamethasone; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D013997:Time Factors; D014196:Trazodone / Q000008:administration & dosage / Q000627:therapeutic use*
D000873:Anthracenes; D008376:Maprotiline; D003907:Dexamethasone; D014196:Trazodone